Takeda Pharmaceutical Co ( (JP:4502) ) has issued an announcement.
Takeda Pharmaceutical Company reported strong financial results for the nine-month period ending December 31, 2024, with significant increases in revenue and operating profit compared to the previous year. The company’s revenue rose by 9.8%, while operating profit surged by 86.3%, reflecting effective operational strategies. The financial forecast for the fiscal year ending March 31, 2025, anticipates continued growth in core financial measures, indicating a positive outlook for stakeholders.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader headquartered in Japan. The company focuses on developing and delivering transformative treatments in the fields of oncology, gastroenterology, neuroscience, rare diseases, plasma-derived therapies, and vaccines.
YTD Price Performance: -2.61%
Average Trading Volume: 17,247
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $42.73B
For detailed information about 4502 stock, go to TipRanks’ Stock Analysis page.